SHZ:002864
Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd · SHZ · Healthcare · CNY · FY for 2025
Figures on this page computed 2026-11-08 00:13 UTC
Last close
n/aCNY
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
21.9xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
13.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
8.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
1.8%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.07Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
What it pays out is the furthest below its sector's middle: 0.28 against 0.54 on the market's range.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.54x
Its own average over 10 years, 741.0M.
- Profit1.17x
Its own average over 10 years, 82.0M.
- Free cash flow0.55x
Its own average over 10 years, 37.4M.
- Debt0.86x
Its own average over 8 years, 133.7M.
- Pricen/a
Its own average over 0 years. Market data
Sales is furthest from its own average, at 1.54 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 123.4 | 110.6 | 103.8 |
| 2018-12-31 | 160.3 | 163.6 | 133.1 |
| 2019-12-31 | 199.9 | 181.6 | 133.5 |
| 2020-12-31 | 219.5 | 200.2 | 132.7 |
| 2021-12-31 | 290.6 | 235.7 | 131.9 |
| 2022-12-31 | 319.0 | 255.9 | 133.4 |
| 2023-12-31 | 321.1 | 279.4 | 150.8 |
| 2024-12-31 | 318.9 | 304.3 | 161.4 |
| 2025-12-31 | 373.5 | 243.6 | 161.5 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Figures behind the shape
Growth
11.2%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate11.2%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Five-year EPS growth raten/a
The stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
One-year change in net income-19.9%
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Returns on capital
13.7%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capital13.7%
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity5.7%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets4.1%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
51.9%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin51.9%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin9.7%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin8.4%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin1.8%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
21.9xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings21.9x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
Price to book1.3x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDA7.7x
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
0.07safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equity0.07
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio3.44
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage50.4x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score3.73
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
45.6%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Payout ratio45.6%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio0.5x
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- CNY
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.